The vaccine is made by Inovio Pharmaceuticals of Plymouth Meeting, Pa., and GeneOne Life Science, of Seoul, South Korea. The working name for the vaccine is GLS-5700. The phase I trial will evaluate the safety and efficacy of the vaccine in 40 healthy subjects. In preclinical animal models, the vaccine produced a robust antibody and T cell response.
J. Joseph Kim, PhD, CEO of Inovio, said, “We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers.”
Federal health officials have previously stated that determining the efficacy of a Zika vaccine could take several years.
More articles on the Zika virus:
FDA authorizes emergency use of in-vitro devices to detect Zika
6 cases of Zika-related birth defects reported in US
Researchers on a medical road trip through Brazil are using mobile labs to track Zika
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.